Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O.
World J Gastroenterol. 2015 Dec 14;21(46):12989-95. doi: 10.3748/wjg.v21.i46.12989.
The Impact of Metabolic Syndrome on the Prognosis of High-Risk Alcoholic Hepatitis Patients: Redefining Alcoholic Hepatitis.
Habib S, Murakami T, Takyar V, Patel K, Dominguez C, Zhan Y, Mehrpour O, Hsu CH.
Gastroenterology Res. 2023 Feb;16(1):25-36. doi: 10.14740/gr1556. Epub 2023 Feb 28.
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, Charlton M.
Gastroenterology. 2017 Apr;152(5):1090-1099.e1. doi: 10.1053/j.gastro.2017.01.003. Epub 2017 Jan 11.
Lymphocyte transformation test with liver-specific protein and phytohaemagglutinin in patients with liver disease.
Thestrup-Pedersen K, Ladefoged K, Andersen P.
Clin Exp Immunol. 1976 Apr;24(1):1-8.
[Effects of a new pharmacological complex (silybin + vitamin-E + phospholipids) on some markers of the metabolic syndrome and of liver fibrosis in patients with hepatic steatosis. Preliminary study].
Trappoliere M, Federico A, Tuccillo C, de Sio I, Di Leva A, Niosi M, D'Auria M, Loguercio C; Real Sud Group 2.
Minerva Gastroenterol Dietol. 2005 Jun;51(2):193-9.
